Adicet Bio (ACET) 2025 Conference Transcript

Summary of Adicet Bio (ACET) Conference Call Company Overview - Adicet Bio is a leader in off-the-shelf gamma delta one CAR T cell therapy, focusing on autoimmune diseases and solid tumors [3][4] Clinical Programs - Clinical Programs: - Off-the-shelf gamma delta one CAR T cell therapy targeting CD20 for lupus and other autoimmune diseases [3][4] - Gamma delta one CAR T targeting CD70 for renal cell carcinoma [4][37] - Preclinical Programs: Two preclinical programs are in development, with data expected later this year [4][46] Advantages of Gamma Delta T Cells - Autoimmune Diseases: - Off-the-shelf availability eliminates the need for leukapheresis and personalized manufacturing [5][6] - Better tolerability with lower incidence and severity of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) [5][6] - Complete depletion of CD19 positive B cells in blood and lymph nodes, which is crucial for durable therapy [11][12] - Solid Tumors: - Innate and adaptive anti-tumor activity helps address tumor heterogeneity [7][8] - Tissue tropism allows activity in nutrient-poor and hypoxic environments [7][8] Targeting Strategy - CD20 Targeting in Autoimmune Diseases: - Strong proof of concept for CAR T efficacy leading to significant disease score improvements [19][20] - Enrollment includes patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN) [17][18] - CD70 Targeting in Renal Cell Carcinoma: - Targeting CD70 using CD27 receptor for potentially more potent activity [38][39] - Expected to have data in the second half of the year, focusing on patients who have progressed on PD-1 and VEGF therapies [41][42] Enrollment and Study Design - Enrollment criteria for SLE include patients who have progressed on at least two therapies [25][26] - Initial data set for SLE and LN expected to include at least six patients with three months follow-up [28][41] Key Learnings and Market Potential - Recent developments in cell therapy for autoimmune diseases indicate significant improvements in disease scores, suggesting a new class of therapies could emerge [35][36] - The potential for gamma delta T cell therapies to address unmet medical needs in multiple autoimmune diseases and solid tumors presents a significant commercial opportunity [35][36] Future Plans and Milestones - Data expected in the second half of the year for both autoimmune and oncology programs [48][49] - Continued focus on expanding clinical data and preclinical programs, with multiple milestones anticipated over the next 18 months [49][50]